As of 2025-05-17, the Intrinsic Value of Eli Lilly and Co (LLY) is 537.55 USD. This LLY valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 757.39 USD, the upside of Eli Lilly and Co is -29.00%.
The range of the Intrinsic Value is 312.96 - 1,776.56 USD
Based on its market price of 757.39 USD and our intrinsic valuation, Eli Lilly and Co (LLY) is overvalued by 29.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 312.96 - 1,776.56 | 537.55 | -29.0% |
| DCF (Growth 10y) | 414.99 - 2,182.01 | 687.42 | -9.2% |
| DCF (EBITDA 5y) | 180.20 - 212.18 | 195.23 | -74.2% |
| DCF (EBITDA 10y) | 268.82 - 329.31 | 296.98 | -60.8% |
| Fair Value | 146.35 - 146.35 | 146.35 | -80.68% |
| P/E | 220.96 - 303.44 | 259.86 | -65.7% |
| EV/EBITDA | 120.51 - 343.58 | 195.37 | -74.2% |
| EPV | 63.20 - 92.69 | 77.94 | -89.7% |
| DDM - Stable | 174.32 - 1,132.57 | 653.45 | -13.7% |
| DDM - Multi | 308.15 - 1,487.49 | 503.22 | -33.6% |
| Market Cap (mil) | 717,998.10 |
| Beta | 0.75 |
| Outstanding shares (mil) | 947.99 |
| Enterprise Value (mil) | 753,420.75 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.82% |
| Cost of Debt | 4.25% |
| WACC | 6.67% |